Praxis Precision Medicines, Inc.
PRAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal. At a $9.82B market cap, Praxis Precision Medicines, Inc. ranks as a mid-cap company within healthcare. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Market Cap
$9.82B
Beta
2.78
P/E (TTM)
—
P/E (Fwd)
-37.85
EPS (TTM)
$-12.98
EPS (Fwd)
$-9.29
ROE
-38.9%
ROA
-25.7%
Cash
$758.6M
Total Debt
$1.1M
Free CF
-$199.4M
52W Change
763.3%
Annual Financials
Cash vs Debt
Where PRAX stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, PRAX finished 14.47% above its 150-day moving average ($321.36) and 21.48% above its 200-day moving average ($302.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRAX overbought or oversold?
At the August 28, 2026 close, PRAX's RSI(14) was 52.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Praxis Precision Medicines, Inc. holds $758.6M in cash against $1.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$199.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -38.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, PRAX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRAX.